Проект за продуктово разработване | Област на продуктово разработване | Фаза 1 | Фаза 2 | Фаза 3 | Подаване за регистрация | ||||
---|---|---|---|---|---|---|---|---|---|
Eptinezumab (anti-CGRP mAb) | Migraine prevention | Filing | |||||||
Механизъм на действие Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. |
|||||||||
Eptinezumab (anti-CGRP mAb)* | Migraine prevention (Asia) | 3 | |||||||
Механизъм на действие Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. *Three phase III clinical trials, supporting registration in Asia, including China and Japan: SUNLIGHT, SUNRISE, and SUNSET trials. |
|||||||||
Eptinezumab (anti-CGRP mAb) | Episodic cluster headache | 3 | |||||||
Механизъм на действие Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. |
|||||||||
Lu AG09222 (anti-PACAP mAb) | Migraine prevention | 2 | |||||||
Механизъм на действие Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology. |
Проект за продуктово разработване | Област на продуктово разработване | Фаза 1 | Фаза 2 | Фаза 3 | |||||
---|---|---|---|---|---|---|---|---|---|
Brexpiprazole* | Agitation in Alzheimer's disease | 3 | |||||||
Механизъм на действие Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. |
|||||||||
Brexpiprazole* | PTSD | 3 | |||||||
Механизъм на действие Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonergic, dopaminergic, and especially the noradrenergic systems are believed to be involved in PTSD (post-traumatic stress disorder) symptomatology with re-experiencing, Negative cognition and mood, Avoidance and Arousal. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. |
|||||||||
Aripiprazole 2-month injectable* | Schizophrenia + Bipolar I disorder | 1 | |||||||
Механизъм на действие Aripiprazole is a small molecule. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at serotonin 5-HT2A receptors. A 2-month formulation will serve as a treatment option when treating patients with Schizophrenia or Bipolar I disorder where long-acting treatment is needed. *Pivotal phase Ib study finalized; Lundbeck and Otsuka Pharmaceutical are planning to submit the aripiprazole 2-month injectable formulation to the European Medicines Agency (EMA) for marketing authorization application (MAA) review and to submit the NDA for review by the U.S. Food & Drug Administration (FDA). |
|||||||||
Lu AF28996 (D1-D2 agonist) | Parkinson's disease | 1 | |||||||
Механизъм на действие Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients. |
|||||||||
Lu AG06466 (MAGL inhibitor)* | Focal epilepsy, PTSD, MS spasticity | 1 | |||||||
Механизъм на действие Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG on CB1 and CB2 receptors may restore altered neuronal transmission and decrease neuroinflammation and thereby it may produce beneficial effects across a range of symptoms and related indications including post-traumatic stress disorder (PTSD), focal epilepsy, and spasticity in patients with multiple sclerosis (MS). * PTSD, focal epilepsy, and MS spasticity Ph1b studies have been initiated. |
Проект за продуктово разработване | Област на продуктово разработване | Фаза 1 | Фаза 2 | Фаза 3 | |||||
---|---|---|---|---|---|---|---|---|---|
Lu AF82422 (anti-alpha-synuclein mAb) | Synucleinopathies (MSA) | 2 | |||||||
Механизъм на действие Lu AF82422 is a monoclonal antibody (mAb) targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Multiple System Atrophy (MSA), Parkinson’s disease and other neurodegenerative disorders. |
|||||||||
Lu AF87908 (anti-Tau mAb) | Tauopathies | 1 | |||||||
Механизъм на действие Lu AF87908 is a monoclonal antibody (mAb) targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders. |
Проект за продуктово разработване | Област на продуктово разработване | Фаза 1 | Фаза 2 | Фаза 3 | |||||
---|---|---|---|---|---|---|---|---|---|
Lu AG22515 (CD40L inhibitor)* | Neurology | 1 | |||||||
Механизъм на действие Lu AG22515 is a CD40L inhibitor which interferes with the activation of the adaptive immune response by blocking the CD40L/CD40 co-stimulatory interaction on immune cells; an interaction which plays a role in the pathophysiology of several immune-mediated diseases. * CD40L/serum-albumin bispecific antibody-fragment ((scFv)2-Fab)) based on AprilBio’s SAFA™ technology platform. |
Изследването и разработването на нови и подобрени лекарства е в основата на нашата дейност.
Лундбек е глобална фармацевтична компания, специализирана в мозъчни заболявания.
Пътят към здравето на мозъка започва с разбиране на заболяванията в мозъка.